Last reviewed · How we verify

Chengdu Kanghong Pharmaceutical Group Co., Ltd. — Portfolio Competitive Intelligence Brief

Chengdu Kanghong Pharmaceutical Group Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 2 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Hydrochloride Carliprazine capsules Hydrochloride Carliprazine capsules phase 3 Atypical antipsychotic Dopamine D2/D3 receptor partial agonist; Serotonin 5-HT1A receptor partial agonist Psychiatry/Neurology
Aripiprazole tablets Aripiprazole tablets phase 3 Atypical antipsychotic Dopamine D2 receptor (partial agonist); Serotonin 5-HT1A receptor (partial agonist); Serotonin 5-HT2A receptor (antagonist) Psychiatry / Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Acacia Pharma Ltd · 1 shared drug class
  2. Alexza Pharmaceuticals, Inc. · 1 shared drug class
  3. Alkermes, Inc. · 1 shared drug class
  4. All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Benaroya Research Institute · 1 shared drug class
  7. BioXcel Therapeutics Inc · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chengdu Kanghong Pharmaceutical Group Co., Ltd.:

Cite this brief

Drug Landscape (2026). Chengdu Kanghong Pharmaceutical Group Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chengdu-kanghong-pharmaceutical-group-co-ltd. Accessed 2026-05-17.

Related